- Nontuberculous mycobacteria
Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001-2013.
Emerg Infect Dis. 2019 07;25(7):
Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.
BMC Pharmacol Toxicol. 2019 06 03;20(1):37
Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease.
J Med Econ. 2019 May 16;:1
Radiologic types of Mycobacterium xenopi pulmonary disease: different patients with similar short-term outcomes.
Eur J Clin Microbiol Infect Dis. 2018 Dec 14;:
Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.
Respir Med. 2018 Dec;145:80-88
Eur Respir J. 2018 Nov 28;:
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study.
Am J Respir Crit Care Med. 2018 Sep 14;:
Adjuvant lung resection in the management of nontuberculous mycobacterial lung infection: A retrospective matched cohort study.
Respir Med. 2018 Sep;142:1-6
Health Care Utilization and Expenditures Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in the United States.
J Manag Care Spec Pharm. 2018 Jul 20;:1-12
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.
Eur Respir J. 2018 Mar;51(3):
Clinician Investigator, Krembil Research Institute (Krembil)
Director Toronto Western Hospital Nontuberculous Mycobacterial Clinical and Research Program